Nautilus Current Deferred Revenue from 2010 to 2024
| NAUT Stock | USD 2.24 0.06 2.61% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -853.2 K | Current Value -810.5 K | Quarterly Volatility 931.5 K |
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
Nautilus | Current Deferred Revenue |
Latest Nautilus Biotechnology's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Nautilus Biotechnology over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Nautilus Biotechnology's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nautilus Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Nautilus Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 694,351 | |
| Coefficient Of Variation | 134.15 | |
| Mean Deviation | 625,972 | |
| Median | 936,000 | |
| Standard Deviation | 931,481 | |
| Sample Variance | 867.7B | |
| Range | 3.7M | |
| R-Value | (0.43) | |
| Mean Square Error | 759.9B | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | (90,004) | |
| Total Sum of Squares | 12.1T |
Nautilus Current Deferred Revenue History
About Nautilus Biotechnology Financial Statements
Nautilus Biotechnology shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -853.2 K | -810.5 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.